GlassScriptPhysician profile
Carmelo J Blanquicett
NPI 1962846196
$24,026.12
in general payments reported to CMS, 2019-2025
57 companies · $2,974 in 2025
The $2,974 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $894 · 2020: $1,690 · 2021: $14K · 2023: $784 · 2024: $4,118 · 2025: $2,974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,305 · Consulting Fee: $2,000 · Long Term Medical Supply Or Device Loan: $1,196 · Education: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,304.55 |
| Consulting Fee | $2,000.00 |
| Long Term Medical Supply Or Device Loan | $1,196.40 |
| Education | $373.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16,367.95 | 2019-2025 | |
| Histosonics, INC. | $2,000.00 | 2025 | |
| Incyte Corporation | $452.84 | 2020-2025 | Monjuvi, Jakafi |
| Lilly USA, LLC | $399.37 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $390.70 | 2023-2025 | Enhertu |
| Genentech USA, INC. | $299.89 | 2019 | |
| Exelixis INC. | $281.50 | 2021-2024 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $261.30 | 2024 | |
| Pfizer INC. | $254.18 | 2023-2025 | |
| Celgene Corporation | $253.29 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $247.39 | 2023-2025 | Imfinzi, Calquence |
| Glaxosmithkline, LLC. | $181.25 | 2024-2025 | Jemperli, Ojjaara, Zejula |
| Novocure INC. | $169.82 | 2024-2025 | Optune Lua (Novottf-200t) |
| Abbvie INC. | $166.49 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $159.38 | 2019-2024 | Ultomiris |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $136.98 | 2020-2021 | |
| Eisai INC. | $118.28 | 2023-2024 | |
| Janssen Biotech, INC. | $115.71 | 2024-2025 | Carvykti, Erleada, Akeega |
| Takeda Pharmaceuticals U.S.A., INC. | $112.99 | 2024-2025 | Alunbrig, Ninlaro |
| Sobi, INC | $109.86 | 2024 | |
| Kite Pharma, INC. | $101.36 | 2023-2024 | Yescarta |
| E.R. Squibb & Sons, L.L.C. | $100.55 | 2023-2025 | Opdivo |
| Fennec Pharmaceuticals, INC. | $97.29 | 2024-2025 | Pedmark, Fyarro |
| Merck Sharp & Dohme LLC | $96.43 | 2024 | Keytruda, Welireg |
| Array Biopharma INC | $74.50 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Springworks Therapeutics, INC. | $73.01 | 2024-2025 | Ogsiveo |
| Alnylam Pharmaceuticals INC. | $71.75 | 2024-2025 | Onpattro, Givlaari |
| Sumitomo Pharma America, INC. | $62.50 | 2023-2024 | Orgovyx |
| Regeneron Healthcare Solutions, INC. | $56.81 | 2023-2024 | Libtayo |
| Stemline Therapeutics INC. | $46.83 | 2023-2024 | Orserdu |
| Kyowa Kirin, INC. | $46.06 | 2024 | Poteligeo |
| Pharmacosmos Therapeutics INC. | $43.93 | 2023-2024 | Monoferric |
| Amneal Pharmaceuticals LLC | $42.06 | 2024 | Avastin |
| Pharmaessentia USA Corporation | $40.88 | 2024 | Besremi |
| Tempus Ai, INC | $39.96 | 2024 | |
| Janssen Scientific Affairs, LLC | $39.57 | 2025 | Carvykti, Talvey, Tecvayli |
| Janssen Pharmaceuticals, INC | $35.20 | 2023-2024 | Xarelto |
| Legend Biotech USA INC. | $31.89 | 2025 | Carvykti |
| Menarini Silicon Biosystems, INC. | $30.75 | 2025 | |
| Beone Medicines USA, INC. | $29.91 | 2025 | Brukinsa |
| Blueprint Medicines Corporation | $29.18 | 2023 | Ayvakit |
| Deciphera Pharmaceuticals INC. | $28.86 | 2024 | Qinlock |
| Rigel Pharmaceuticals, INC. | $28.59 | 2024 | Rezlidhia, Tavalisse |
| Gilead Sciences, INC. | $27.34 | 2024 | |
| Geron Corporation | $25.01 | 2025 | Rytelo |
| Servier Pharmaceuticals LLC | $24.95 | 2024 | |
| Accord Healthcare, INC. | $24.13 | 2023 | |
| Taiho Oncology, INC. | $21.99 | 2024 | |
| Beigene USA, INC. | $21.82 | 2024 | Brukinsa |
| Karyopharm Therapeutics INC. | $21.19 | 2024 | Xpovio |
| Agios Pharmaceuticals, INC. | $21.13 | 2024 | |
| Aveo Pharmaceuticals, INC. | $21.01 | 2024 | |
| Telix Pharmaceuticals | $20.20 | 2024 | Illuccix |
| Emd Serono, INC. | $19.33 | 2023 | Bavencio |
| Progenics Pharmaceuticals, INC. | $18.02 | 2023 | |
| Emmaus Medical, INC. | $17.00 | 2024 | Endari |
| Seagen INC. | $15.96 | 2023 | Padcev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmelo Blanquicett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.